Lake Street lowered the firm’s price target on Castle Biosciences (CSTL) to $35 from $40 and keeps a Buy rating on the shares. The firm adjusted its price target after Castle reported Q1 revenues “well ahead of consensus” and raised 2025 revenue guidance largely to reflect multiple compression in the comp group, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences price target lowered to $37 from $42 at Canaccord
- Castle Biosciences Reports Strong Q1 2025 Growth
- Castle Biosciences to acquire Capsulomics, terms undisclosed
- Castle Biosciences reports Q1 adjusted EPS (20c), consensus (7c)
- Castle Biosciences raises FY25 revenue view to $287M-$297M from $280M-$295M